VCYTHealthcare · Diagnostics & ResearchThe 12 Wall Street analysts covering Veracyte, Inc. hold a median 12-month price target of $55 — +29.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 96 of 100 as at 5 Sept 2026 — among the strongest tenth. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Veracyte, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Value (92): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.
Accruals (64): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
Size (29): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on VCYT, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +29.3% from it.
Of the 20 most recent actions, 4 moved their price target up and 4 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 4 Aug 2026 | Morgan Stanley | Maintains | Underweight | $47 → $44 |
| 4 Aug 2026 | Piper Sandler | Maintains | Overweight | $66 → $54 |
| 4 Aug 2026 | Stephens & Co. | Maintains | Overweight | $68 → $55 |
| 3 Aug 2026 | Canaccord Genuity | Maintains | Hold | $60 → $50 |
| 31 July 2026 | Needham | Maintains | Buy | $57 → $69 |
| 30 July 2026 | Needham | Maintains | Buy | $57 → $69 |
| 15 July 2026 | Piper Sandler | Initiates | Overweight | — |
| 15 July 2026 | Piper Sandler | Initiates | Overweight | $66 |
| 14 July 2026 | Canaccord Genuity | Maintains | Hold | — |
| 14 July 2026 | Canaccord Genuity | Maintains | Hold | $42 → $60 |
| 9 July 2026 | Morgan Stanley | Maintains | Underweight | — |
| 9 July 2026 | Morgan Stanley | Maintains | Underweight | $37 → $47 |
| 29 June 2026 | Guggenheim | Maintains | Buy | — |
| 1 June 2026 | Needham | Maintains | Buy | — |
| 28 May 2026 | Needham | Reiterates | Buy | — |
| 6 May 2026 | Canaccord Genuity | Maintains | Hold | — |
| 6 May 2026 | UBS | Maintains | Buy | — |
| 20 Apr 2026 | Canaccord Genuity | Maintains | Hold | — |
| 13 Apr 2026 | Jefferies | Initiates | Buy | — |
| 1 Apr 2026 | Needham | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. VCYT appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 4 Sept 2026, Veracyte, Inc. returned +34.9% against +20.0% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 24% of US stocks
Cheaper than 21% of US stocks
Cheaper than 38% of US stocks
Cheaper than 10% of US stocks
Higher than 63% of US stocks
Higher than 54% of US stocks
Higher than 84% of US stocks
Higher than 73% of US stocks
Higher than 82% of US stocks
Higher than 61% of US stocks
Higher than 71% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Veracyte, Inc. has a market value of $3.6B and an enterprise value of $3.1B.
Revenue in the twelve months to 30 June 2026: $561.9M. The latest quarter grew 15.5% year on year.
Net income over the same four quarters: $114.5M, a 20.4% net margin.
Diluted earnings per share, trailing twelve months: $1.41.
Free cash flow in the twelve months to 30 June 2026: $166.0M.
Trailing P/E: 31.9×; forward P/E: 22.9× — the forward figure prices analyst consensus estimates, not reported earnings.
Veracyte, Inc. employs 755 people — $744K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Veracyte, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Veracyte, Inc. announced it will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on Tuesday, September 15, 2026, at 7:00 a.m. Eastern Time.
Why it matters — The company's participation in a major investor conference provides a public platform for management to discuss its business with the investment community.
Zacks Investment Research published an analysis assessing whether Veracyte stock is worth adding to portfolios. The piece notes that sales momentum in Veracyte's Afirma and Decipher products supports growth, while citing competition, macroeconomic pressures, and rising investments as key concerns.
Why it matters — VCYT watchers would care because the analysis weighs the company's growth drivers (Afirma and Decipher momentum) against the competitive and macro headwinds it faces.
Veracyte's stock dropped 25.3% over the past month. The report notes the sell-off improves the entry price given strong core test demand and earnings growth, though it flags valuation, reimbursement, and launch risks.
Why it matters — The sharp decline raises the question for VCYT watchers of whether the lower share price represents an entry opportunity or reflects lingering reimbursement and launch risks.
Zacks reports that Veracyte stock has become technically oversold after a 30.2% decline over four weeks, which suggests heavy selling pressure may be exhausting. This oversold condition, combined with Wall Street analysts broadly revising earnings estimates upward, points to a possible near-term trend reversal.
Why it matters — For VCYT watchers, the oversold technical reading alongside upward analyst estimate revisions could signal the end of the recent downtrend.
Seeking Alpha highlights that Veracyte's core Decipher and Afirma tests are generating double-digit growth with improving margins, positioning the company as a potential long-term cash flow machine. The piece also notes that Prosigna and TrueMRD present additional upside not yet reflected in management's 2026 testing-revenue guidance.
Why it matters — VCYT watchers would care because sustained double-digit growth and margin improvement in the core test portfolio, plus unguided upside from Prosigna and TrueMRD, point to a strengthening revenue and cash flow trajectory.
The 12 Wall Street analysts covering Veracyte, Inc. have a median 12-month price target of $55, with estimates ranging from $44 to $70. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 12 analysts covering Veracyte, Inc., 10 rate it a Buy, 1 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Veracyte, Inc. 96 out of 100 across roughly 4,600 US stocks as at 5 Sept 2026. None of this is personal advice — it does not consider your circumstances.
As at 5 Sept 2026, Veracyte, Inc. ranks 96 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (92 of 100).
No one can know that. What the data says: the median 12-month target from 12 analysts implies +29.3% from the last close, and Ticker Nerd's factor model ranks Veracyte, Inc. 96 out of 100 as at 5 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Veracyte, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for VCYT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $44 to $70 over the next 12 months.
Veracyte, Inc. returned +34.9% over the 12 months to 4 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.
Veracyte, Inc. is a precision diagnostics company that develops genomic tests to help clinicians answer critical questions in cancer and other diseases.
The most recent item we track (GlobeNewsWire, 1 Sept 2026): "Veracyte to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference". Veracyte, Inc. announced it will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on Tuesday, September 15, 2026, at 7:00 a.m. Eastern Time.
Veracyte, Inc. is a precision diagnostics company that develops genomic tests to help clinicians answer critical questions in cancer and other diseases. Veracyte’s current portfolio includes laboratory-developed tests for thyroid, prostate, bladder, and breast cancer, as well as tests for lung disease and lung cancer-related decision support. The company also provides products and services such as Afirma, Decipher, Percepta, Envisia, Prosigna, Immunoscore, and nCounter analysis capabilities, supporting diagnosis, prognosis, and treatment selection across multiple care settings. Its work is centered on using genomic and clinical data to reduce diagnostic uncertainty and improve decision-making for physicians, pathologists, and patients. Headquartered in South San Francisco, California, Veracyte operates as a global diagnostics business with a focus on molecular testing, evidence generation, and clinical utility in oncology and related specialties.
CEO Mr. Marc A. Stapley · 755 employees · United States · https://www.veracyte.com
